Abstract
Multiple myeloma (MM) is a clonal B-cell malignancy with a terminally differentiated plasma cell (PC) phenotype characterized by the production of either intact immunoglobulins (Ig) or free light chains (FLC). The annual incidence is 5 cases per 100,000 persons. Median age at diagnosis is approximately 70 years. An evolutionary model in which MM is the result of the transformation of a previous condition of monoclonal gammopathy of undetermined significance (MGUS) is virtually the basis of almost all cases. In about 15% of cases diagnosis is suspected based on routine laboratory exams. In the remaining 85% most common clinical manifestations include hypercalcemia, renal failure, anemia, or bone lesions (defined as CRAB criteria). According to the revised International Myeloma Working Group (IMWG) diagnostic criteria, MM requiring the immediate start of therapy is defined by the presence of clonal bone marrow (BM) PCs ≥10%, or biopsy-proven bony or extramedullary plasmacytoma, along with at least one CRAB criteria or at least one of the new biomarkers of malignancy, including BM PCs ≥60% and/or involved/uninvolved serum FLC (sFLC) ratio ≥100 and/or >1 focal lesions on magnetic resonance (MRI) studies. Converserly, smoldering MM does not require therapy (with the exception of controlled clinical trials) and is defined by the presence of serum monoclonal protein (M-protein) ≥30 g/L or urinary M-protein ≥500 mg per 24 h and/or clonal BM PCs in the range between 10 and 60%, and absence of both CRAB criteria and biomarkers of malignancy or amyloidosis. Treatment paradigm includes different combinations of novel agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and monoclonal antibodies (mAb), combined or not with autologous stem cell transplantation (ASCT). The main treatment end point is to achieve the deepest response early in the course of the disease and maintain it as much long as possible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hallek M, Bergsagel PL, Anderson KC, et al. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):1–16.
Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–62.
Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–76.
Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/index.html.
Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.
Rajkumar SV, Dimopolous MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538–48.
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7.
Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28(33):4976–84.
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126(3):348–54.
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9.
Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.
Cavo M, Rajkumar SV, Palumbo A, et al. International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063–73.
Moreau P, San Miguel J, Sonneveld P, et al. ESMO guidelines committee. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–61.
Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tacchetti, P., Cavo, M. (2019). Multiple Myeloma: Clinical Aspects. In: Nanni, C., Fanti, S., Zanoni, L. (eds) Molecular Imaging in Multiple Myeloma. Springer, Cham. https://doi.org/10.1007/978-3-030-19019-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-19019-4_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19018-7
Online ISBN: 978-3-030-19019-4
eBook Packages: MedicineMedicine (R0)